1. P2X7 receptor knockdown suppresses osteoclast differentiation by inhibiting autophagy and Ca²⁺/calcineurin signaling.
   Yonggang Ma et al, 2022, Mol Med Rep CrossRef
2. How zoledronic acid improves osteoporosis by acting on osteoclasts
   Biao Wang et al, 2022, Front. Pharmacol. CrossRef
3. The Ethanol Extracts of Osmanthus fragrans Leaves Ameliorate the Bone Loss via the Inhibition of Osteoclastogenesis in Osteoporosis
   Yo-Seob Seo et al, 2023, Plants CrossRef
4. Fine‐tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis
   Aleena Anwar et al, 2023, Journal Cellular Physiology CrossRef
5. Revisiting Resveratrol as an Osteoprotective Agent: Molecular Evidence from In Vivo and In Vitro Studies
   Haryati Ahmad Hairi et al, 2023, Biomedicines CrossRef
6. Inhibiting Osteolytic Breast Cancer Bone Metastasis by Bone‐Targeted Nanoagent via Remodeling the Bone Tumor Microenvironment Combined with NIR‐II Photothermal Therapy
   Yaoxun Zeng et al, 2023, Small CrossRef
7. Bone Disease in HIV: Need for Early Diagnosis and Prevention
   Georgios Schinas et al, 2024, Life CrossRef
8. Inhibitory action of methylene bisphosphonic acid on metabolic activity and viability of J774A.1 cells
   D. O. Labudzynskyi et al, 2024, Ukr.Biochem.J. CrossRef
9. Tetrahydroberberine Prevents Ovariectomy-Induced Bone Loss by Inhibiting RANKL-Induced Osteoclastogenesis and Promoting Osteoclast Apoptosis
   Qihang Wu et al, 2024, J. Agric. Food Chem. CrossRef
10. Identification of novel RANKL inhibitors through in silico analysis
    Yingying Jiang et al, 2024, Bioorganic Chemistry CrossRef
11. Zoledronic Acid Inhibits Lipopolysaccharide‐Induced Osteoclastogenesis by Suppressing Macrophage NLRP3‐Mediated Autophagy Pathway
    Yuting Cheng et al, 2024, Immunity Inflam & Disease CrossRef